Withdrawal Symptoms After Selank: What Does Research Say?
One of the most frequently asked questions regarding substances affecting mood, anxiety, or cognitive function is whether their discontinuation can cause withdrawal symptoms or lead to addiction. Based on currently available scientific data, there is no evidence to suggest that Selank causes physical dependence or withdrawal syndrome characteristic of benzodiazepines, opioids, or other addictive psychoactive substances [1–4].
Selank was originally developed as an anxiolytic peptide and has been extensively studied for its effects on anxiety, stress regulation, and cognitive function. Unlike many conventional anxiolytic drugs, Selank appears to act as a regulatory neuropeptide rather than by directly stimulating or inhibiting the central nervous system [1].
Experimental studies suggest that Selank primarily acts by modulating GABAergic signaling, endogenous opioid peptides such as enkephalins, and neuroplasticity-related pathways [1,2]. These mechanisms differ significantly from benzodiazepines, which bind directly to the benzodiazepine sites of GABA-A receptors and are well-known for inducing tolerance and withdrawal symptoms upon prolonged use.
Is Selank addictive?
Current scientific data does not indicate that Selank has addictive properties.
In clinical trials involving patients with generalized anxiety disorder and neurasthenia, Selank was shown to reduce anxiety severity and improve mental state without signs of dependence, abuse, or withdrawal symptoms [3]. Researchers also observed psychostimulant and antiasthhenic effects without a clear sedative effect, which often accompanies substances that can lead to dependence.
Additional support is provided by animal studies. Selank, when used in combination with benzodiazepines, has been shown to enhance their anxiolytic effects while reducing their sedative and muscle-relaxant effects [4]. These findings suggest that Selank behaves differently from traditional sedatives and possesses a unique neuropharmacological profile.
Can stopping Selank cause withdrawal symptoms?
Currently, no published studies have described a clinically significant withdrawal syndrome after discontinuing Selank.
In the scientific literature, there have also been no reported cases of rebound anxiety, physical dependence, compulsive use, or the need for dose escalation [1-4].
However, the absence of evidence should be distinguished from evidence that withdrawal symptoms can never occur. Because long-term human studies are still limited, scientists cannot completely rule out the possibility that some individuals may notice changes in subjective well-being after discontinuing Selank.
For example, a person who experienced less severe anxiety while using any intervention may notice a return of previous symptoms after it ends. This situation does not necessarily indicate withdrawal symptoms and may simply reflect a relapse of the original problem that had previously improved.
Why Does Selank Seem to Have a Low Potential for Addiction?
Several features may explain Selank's seemingly low addictive potential.
First, Selank appears to regulate neurotransmitter systems, rather than causing abrupt increases in reward system neurochemicals, which often contribute to the development of addiction.
Secondly, current data indicate that Selank does not cause explicit sedation, euphoria, intoxication, or cognitive impairment, which are characteristics often associated with substances of high abuse potential [1,3].
Third, Selank appears to work by modulating natural biological systems, including GABA receptor activity, enkephalin metabolism, and neuroplasticity pathways, which may promote emotional balance without causing significant disruptions in brain chemistry [1–3].
Current Scientific Findings
Based on available studies in humans and animals, Selank does not appear to be an addictive substance and has not been shown to cause clinically recognizable withdrawal symptoms [1–4]. Nevertheless, further long-term studies are needed to better assess its safety profile, especially for prolonged use and after its discontinuation.
Is Selank detected in drug tests?
Can Selank lead to a positive drug test?
Another frequently asked question is whether Selank can cause a positive result on drug tests performed in the workplace, sports, law enforcement, or forensic medicine.
According to currently available data, Selank is not known to cause positive results in standard screening tests.
Most routine drug tests are designed to detect specific substances or their metabolites, including amphetamines, cocaine metabolites, cannabinoids, opioids, benzodiazepines, phencyclidine (PCP), and some synthetic drugs.
Selank is a synthetic heptapeptide built from seven naturally occurring amino acids arranged in the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) [5].
Since its structure isn't related to compounds commonly screened for in routine toxicology testing, there is currently no evidence to suggest that Selank causes false positives for the most frequently tested substances.
Does Selank show up as a benzodiazepine on drug tests?
There is no evidence indicating that Selank causes positive results on benzodiazepine tests.
This question arises often because Selank exhibits anxiolytic properties and affects GABAergic signaling. Mechanistic studies, however, show that Selank acts differently than benzodiazepines [1]. Although it modulates GABA receptor activity through positive allosteric modulation, its interactions appear to differ from classical binding at the benzodiazepine sites.
Furthermore, animal studies have shown that Selank can modify the effects of diazepam and other psychoactive substances in a way that goes beyond simple summation of effects, further confirming its unique pharmacological profile [1,4].
Can Specialized Laboratories Detect Selank?
Although Selank is not known to appear in routine drug tests, this does not mean that its detection is impossible.
Theoretically, specialized analytical techniques such as liquid chromatography coupled with mass spectrometry (LC-MS) could potentially identify peptide compounds if research protocols were specifically designed for their detection. However, these types of tests are highly specialized and differ significantly from standard tests performed in workplaces, clinics, or during routine screenings.
Currently, there are no published studies indicating that Selank is routinely included in conventional toxicology panels.
Does Selank Affect Anti-Doping Tests?
The available literature does not provide evidence that Selank routinely causes positive results in standard doping tests. However, it should be noted that anti-doping organizations regularly update their lists of prohibited substances and testing procedures.
For this reason, individuals participating in elite sports should always check the current regulations of their sports organization rather than assuming that all peptides are automatically permitted.
Current Scientific Findings
Based on currently available data, Selank is not known to cause positive results in routine drug tests, as it is a synthetic heptapeptide with a structure different from substances commonly included in standard screening panels [1,5]. Nevertheless, specialized analytical methods could theoretically detect peptide compounds if research protocols were specifically developed for this purpose.
Disclaimer
This material is for educational and informational purposes only and should not be interpreted as medical advice, therapeutic recommendation, or confirmation of safety or efficacy. Selank remains a research peptide in many countries, and a significant portion of available data comes from preclinical studies and limited human trials. Current research suggests that Selank has a favorable safety profile, low addiction potential, and no known association with positive results in routine drug tests. However, long-term safety data are still limited, and further clinical studies are necessary to fully determine its addictive potential, withdrawal effects, and detectability in specialized testing.
For Research Purposes Only: The Selank products offered by Semax Polska are intended solely for laboratory and scientific research. They are not approved for human consumption, medical use, or for the diagnosis, treatment, or prevention of any disease. No claims are made regarding the diagnosis, treatment, prevention, or cure of any medical condition.
References
[1] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. F. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[2] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[3] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[4] Kost, N. V., Sokolov, O. Y., Zozulya, S. A., & Myasoedov, N. F. (2025). Combined Action of Benzodiazepine Tranquilizers and Peptide Anxiolytic Selank in BALB/c Mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783
[5] National Center for Biotechnology Information. (2026). PubChem Compound Summary for CID 11765600, Selank. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/Selank